The US FDA’s recommendations for clinical switching study designs and human factors study testing of proposed interchangeable biosimilar products elicited strong, and sometimes divergent, views from the biopharma industry.
In comments on FDA’s January draft guidance, “Considerations in Demonstrating Interchangeability With a Reference Product,” industry groups and companies generally...





